You-Lin Tain

asymmetric dimethylarginine, nitric oxide, oxidative stress, pediatric nephrology


In 1992, You-Lin Tain graduated from China Medical University, Taiwan with an M.D. degree. He later received his residency training in pediatrics and fellow training in pediatric nephrology at Chang Gung Memorial Hospital (CGMH), Taiwan. From 1999 to 2002, Dr. Tain worked as an attending pediatrician at Kaohsiung CGMH, Taiwan. At the same time, he attained a master’s degree in biomedicine at the Chang Gung University, Taiwan. In 2003, he came to the U.S. with a pre-doctoral fellowship award from his hospital. In 2007, Dr. Tain graduated from the University of Florida Graduate School of Medicine with a Ph.D. in Physiology. Later he returned to Taiwan and worked at the Kaohsiung CGMH. Presently, he is an Associate Professor of Pediatrics at the Kaohsiung CGMH and Chang Gung University College of Medicine, and the Deputy Director of the Department of Pediatrics, Kaohsiung CGMH, Taiwan. His research interests include pediatric nephrology, free radical medicine, renal physiology, developmental programming, and hypertension. In recent 5 years, Dr. Tain has 14 grants as PI and 6 grants as Co-PI from the National Sciences Council, National Health Research Institute, his hospital, and other resources in Taiwan. All of his projects focus on understanding how the NO/ROS imbalance contributes to hypertension and kidney disease. Five different but concurrently run sets of experiments aim to advance the understanding on NO pathway and NO-related therapies. The five approaches are: 1) The development and refinement of new methodologies to detect NO and other free radicals (e.g., EPR) in humans and experimental animals; 2) The discovery of source of reactive oxygen species (ROS) and its specific corresponding antioxidant for therapeutic use in hypertension and kidney disease; 3) The determination of the role of asymmetric dimethylarginine (ADMA, an endogenous NOS inhibitor) and its-related enzymes (e.g., PRMT and DDAH) in pediatric diseases (e.g., chronic kidney disease, hypertension); 4) The exploration of how NO/ROS imbalance affects epigenetic regulation in programmed hypertension and kidney diseases; and 5) The translational application of NO-related therapies (e.g., L-citrulline, antioxidants, and ADMA-lowering agents) in children with diseases attributed to NO deficiency. Overall, Dr. Tain published 59 reports of which he first and/or corresponding authored on 34 in the past five years.
    • Sources Close sources
      • Show Details Hide Details
    • {{work.publicationDate.year}}-{{work.publicationDate.month}}-{{}} | {{work.workType.value}}
      • Show Details Hide Details
      Translated title ({{worksSrvc.details[work.putCode.value].translatedTitle.languageName}})
      Citation ({{worksSrvc.details[work.putCode.value].citation.citationType.value}}) [Switch view] [Switch view]
      View not available
      {{entVal | latex}}
      Country of publication
      Preferred source
      Source: {{work.sourceName}}
      Preferred source (of {{group.activitiesCount}})
      Show other sources
No publications added yet